此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema

2014年4月14日 更新者:Allergan

A Phase I/II, Open-label, Single Ascending Dose Study Evaluating the Safety, Preliminary Efficacy, and Pharmacokinetics of Intravitreal MP0112 in Patients With Diabetic Macular Edema (DME)

The purpose of this study is to assess the safety and tolerability of MP0112 (a novel, potentially long acting VEGF inhibitor) in patients with diabetic retinal edema.

研究概览

地位

终止

干预/治疗

研究类型

介入性

注册 (实际的)

18

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Maryland
      • Baltimore、Maryland、美国、21287
        • Wilmer Eye Institute
    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • Ophthalmic Consultants of Boston
    • Texas
      • Austin、Texas、美国、78705
        • Retina Research Center
      • Houston、Texas、美国、77030
        • Retina Consultants of Houston

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Male or female age 18 years or older
  • Macular edema due to diabetic retinopathy
  • Best-corrected visual acuity in the study eye of 20/40 to 20/400
  • Central subfield thickness ≥ 250 microns by OCT
  • Females of childbearing potential must have a negative serum pregnancy test at Screening
  • Male subjects must or be: 1) surgically sterilized for at least 6 months, or 2) use an appropriate method of barrier contraception (e.g., condoms with spermicide) and advise any sexual partner of child-bearing potential that she must also use a reliable method of contraception (e.g., hormonal contraceptive, intrauterine device, diaphragm with spermicide) during the study and for 30 days from study drug administration.
  • Ability to understand the nature of the study and give written informed consent
  • Willing, committed, and able to return for ALL clinic visits and complete all study-related procedures

Exclusion Criteria:

  • Any indication of irreversible vision loss such as significant atrophy, scarring, fibrosis, or hyperpigmentation in the fovea
  • Presence of significant ocular abnormalities in the study eye that prevent retinal assessment, including media opacities, cataract, or inadequate papillary dilation
  • Presence of vision loss from another ocular disease other than DME
  • History of any intraocular surgery within 3 months of Baseline
  • History of intraocular injection of anti-VEGF agent or steroids within 3 months of Baseline
  • History of laser photocoagulation for macular edema within 4 months prior to Baseline
  • Uncontrolled hypertension > 140 systolic or > 95 diastolic
  • HbA1C ≥ 12%
  • Creatinine: > 1.5 x upper limit of normal (ULN)
  • Alanine transaminase (ALT), aspartate transaminase (AST), and gamma-glutamyl transferase (GGT): > ULN
  • White blood cells (WBC), hematocrit, and platelets: < lower limit of normal (LLN)
  • Heart rate < 60 beats per minute (bpm) or history of clinically significant bradycardia
  • History of human immunodeficiency virus (HIV), chronic hepatitis B, or chronic hepatitis C infections
  • Subjects with infections requiring hospitalization and/or antibiotic treatment 14 days prior to Baseline
  • Subjects with any medical condition that in the judgment of the investigator could poise unacceptable risk to the subject or compromise interpretation of the data to be collected

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:MP0112(0.04 毫克)
在研究眼中单次玻璃体内注射 0.04 mg MP0112。
Single intravitreal injection of MP0112 in the study eye
实验性的:MP0112(0.15 毫克)
在研究眼中单次玻璃体内注射 0.15 mg MP0112。
Single intravitreal injection of MP0112 in the study eye
实验性的:MP0112(0.4 毫克)
在研究眼中单次玻璃体内注射 0.4 mg MP0112。
Single intravitreal injection of MP0112 in the study eye
实验性的:MP0112(1.0 毫克)
在研究眼中单次 1.0 mg 玻璃体内注射 MP0112。
Single intravitreal injection of MP0112 in the study eye
实验性的:MP0112(2.0 毫克)
在研究眼中单次 2.0 mg 玻璃体内注射 MP0112。
Single intravitreal injection of MP0112 in the study eye
实验性的:MP0112(3.6 毫克)
在研究眼中单次玻璃体内注射 3.6 mg MP0112。
Single intravitreal injection of MP0112 in the study eye

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
大体时间:16 weeks
Safety and tolerability was assessed by vital signs, clinical laboratory evaluations, ophthalmological examinations, intraocular pressure, the presence of anti-drug antibodies and the collection of adverse events. An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events.
16 weeks

次要结果测量

结果测量
措施说明
大体时间
具有阳性结合抗 MP0112 抗体的参与者人数
大体时间:12周
在治疗前(基线)和第 4、8 和 12 周收集血样。 使用酶联免疫吸附测定分析样品的抗 MP0112 抗体。
12周
Best-Corrected Visual Acuity (BCVA)
大体时间:Baseline, Week 16
BCVA was measured using an eye chart and was reported as the number of letters read correctly (ranging from 0 to 100 letters) in the study eye at Baseline and Week 16. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). The higher the letters read correctly on the eye chart the better the vision.
Baseline, Week 16
Change From Baseline in Foveal Thickness as Measured by Optical Coherence Tomography (OCT)
大体时间:Baseline, Week 16
Optical Coherence Tomography (OCT), a laser based non-invasive diagnostic system providing high-resolution imaging sections of the fovea (part of the retina), was performed in the study eye after pupil dilation at Baseline and Week 16. A negative change from Baseline indicated improvement (less foveal thickness).
Baseline, Week 16
Serum Levels of MP0112
大体时间:16 Weeks
Blood samples were collected Pre-treatment (Baseline), Day 1 and 3, Weeks 1, 4, 12, 16. Serum samples (liquid portion of the blood after cells and clotting factors were removed) were sent to a laboratory for analysis. Levels of MP0112 were determined using an enzyme-linked immunosorbent assay.
16 Weeks
Aqueous Humor Levels of MP0112
大体时间:1 Week
Aqueous humor (the thin, watery fluid in the eye) samples were collected from anterior chamber taps and were sent to a laboratory for analysis. Levels of MP0112 were determined using an enzyme-linked immunosorbent assay.
1 Week

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2010年2月1日

初级完成 (实际的)

2010年12月1日

研究完成 (实际的)

2010年12月1日

研究注册日期

首次提交

2010年1月1日

首先提交符合 QC 标准的

2010年1月4日

首次发布 (估计)

2010年1月5日

研究记录更新

最后更新发布 (估计)

2014年5月13日

上次提交的符合 QC 标准的更新

2014年4月14日

最后验证

2014年4月1日

更多信息

与本研究相关的术语

其他研究编号

  • MP0112-CP02

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅